



COVID-19 Monoclonal Antibody (Mab) Protocol Orders
with Risk Factor Scoring
(to be used in event of limited inventory)
(FOR OUTPATIENT IV INFUSION USE ONLY)



1. **FDA Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19**
All Inclusion criteria listed below must be met (check when verified) :

- ☐ Confirmation of COVID-19 via positive PCR or antigen test
- ☐ Treatment within 7 days of symptom onset **Date of symptom onset:** _____
- ☐ Patient symptomatic but not yet progressed to require hospitalization or oxygen therapy.

AND

- ☐ High-risk adult or pediatric patient 12 years and older > 40 kg. High-risk defined by a combination of risk factors as listed below. **Please check all that apply to determine the individual patient's risk score:**

Check All That Apply	Condition	Points	Points that Apply to Patient
	Age 65 years and older	2	
	BMI 35 kg/m and higher	2	
	Diabetes Mellitus	2	
	Chronic Kidney Disease	3	
	Cardiovascular Disease in patient 55 years and older	2	
	Chronic Respiratory Disease in patient 55 years and older	3	
	Hypertension in patient 55 years and older	1	
	Immunocompromised status	4	
	Pregnancy	4	
	Neurodevelopmental Disorder or other condition the confers medical complexity	2	
	Sickle Cell Disease	2	
	Black, Indigenous or Person of Color status	2	
	Health Care Worker	4	
Total Patient's Risk Score			

- ☐ Adults or pediatric patient who **DOES NOT** require an increase in baseline oxygen flow rate due to COVID-19 in those patients on chronic oxygen therapy due to underlying non-COVID-19-related comorbidity.

1. IV Infusion Therapy:

Peripheral IV – start Normal Saline at KVO using a using a polyvinylchloride (PVC) or polyethylene set with or without diethylhexylphthalate (DEHP).

Notify Pharmacy when IV access is established.

No pre-medications necessary. Follow OP IV Therapy Infusion Reaction Protocol in the event of patient adverse reaction to medication.

Vital Signs pre-injection, and then 15 minutes, 30 minutes, and one hour after injection of dose.

A nurse to be in attendance during the first 15 minutes after injection, and then close observation for the remainder of one-hour after injection.



**COVID-19 Monoclonal Antibody (Mab) Protocol Orders
with Risk Factor Scoring
(to be used in event of limited inventory)
(FOR OUTPATIENT IV INFUSION USE ONLY)**

If patient develops flushing of face, chest tightness, chills, fever, dizziness, nausea, diaphoresis, or hypotension, stop infusion and restart normal saline. Take vital signs and notify physician and pharmacist. Monitor until condition resolves.

Have immediately available, T B syringe, 12ml syringe, 22-gauge needles x2, Epinephrine 1:1000 x 1 amp, sterile water x2, Benadryl 50 mg inject x 1 amp, and 3 ml syringe.

3. Patient Consent and Education Prior to Medication Administration:

Follow procedure for obtaining patient consent using the “**COVID Med Consent Form**” for use when procedure specific form is not available. (*Located in the Access Repository*).

You must communicate to the patient information consistent with the “Fact Sheet for Patients and Parents/Caregivers for the Emergency Use Authorization (EUA) of the specific monoclonal antibody that is being provided (and provide a copy of the Fact Sheet) prior to the patient receiving treatment (*Located in the Access Repository*).

4. Monoclonal Therapy Ordered – Administer Bebtelovimab:

Bebtelovimab 175 mg IV push over at least 1 minute X 1 dose.

5. Preparation:

Remove Bebtelovimab vial from refrigerated storage and allow to equilibrate to room temperature for approximately 20 minutes before preparation. Do not shake vial or expose to extreme heat.

6. Administration Instructions:

Withdraw 2 ml from the vial into a disposable syringe.

Discard any product remaining in the vial.

Product is preservative free and should be administered immediately.

Administer Bebtelovimab 175 mg IV Push over at least 1 minute X 1 dose.

Flush line with normal saline after injection of Bebtelovimab to insure delivery of the total dose.

Observe patient for at least 1 hour after IV push injection is complete.

7. Patient Discharge Instructions:

Provide patient a copy of the **EUA Bebtelovimab Fact Sheet**.

Instruct patient to continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect “high touch” surfaces, and frequent handwashing) according to CDC guidelines.

Physician Signature

Date / Time

LAST, FIRST MNAME ROOM-BED S
V1234 t 04/30/2008 M1234 m
04/30/2008 00M 07D

Rev 05/10/2022

PO_9280_EFR